Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.86 Average Price Target from Brokerages

by · The Cerbat Gem

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) has received a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $12.6667.

A number of equities analysts have weighed in on CATX shares. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Monday, November 24th. They set a “buy” rating and a $12.00 target price for the company. UBS Group restated a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. HC Wainwright raised their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, January 30th. B. Riley Financial reduced their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Finally, Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 target price on the stock.

Read Our Latest Research Report on CATX

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $5.40 on Tuesday. The company has a quick ratio of 8.66, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a one year low of $1.60 and a one year high of $6.16. The business’s fifty day moving average price is $3.69 and its 200-day moving average price is $3.29.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently modified their holdings of the company. Aigen Investment Management LP bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $28,000. Russell Investments Group Ltd. grew its position in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares in the last quarter. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the fourth quarter worth about $31,000. AXQ Capital LP increased its stake in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after acquiring an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics in the 4th quarter worth about $35,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Featured Articles